PMID- 26707305
OWN - NLM
STAT- MEDLINE
DCOM- 20160803
LR  - 20151228
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 47
IP  - 10
DP  - 2015 Dec
TI  - Fluvastatin Decreases Oxidative Stress in Kidney Transplant Patients.
PG  - 2870-4
LID - 10.1016/j.transproceed.2015.10.027 [doi]
LID - S0041-1345(15)01019-2 [pii]
AB  - OBJECTIVE: Oxidative stress has been suggested to have a pivotal role in the
      development of cardiovascular disease in kidney transplant patients (KTPs). The
      effects of fluvastatin on oxidative status in KTPs have not been well evaluated. 
      The aim of the present study was to evaluate the effects of fluvastatin on
      oxidative status by investigating erythrocyte superoxide dismutase (SOD),
      erythrocyte glutathione peroxidase (GPx), serum paraoxonase (PON1), and serum
      arylesterase (ARE), along with lipid peroxidation products, serum
      malonldialdehyde, and apolipoprotein B malondialdehyde (ApoB MDA). METHODS:
      Eighteen KTPs were included in the present study. Blood samples were obtained
      after 1 night's fast. Erythrocyte SOD, erythrocyte GPx, serum PON1, serum ARE,
      serum MDA, and ApoB MDA were measured using methods described previously.
      Paired-sample t test was used for comparing the changes from week 0 to week 4 of 
      parameters that might be associated with fluvastatin treatment. RESULTS: The
      present study has shown that erythrocyte SOD and GPx, and serum PON1 and ARE
      activities increased at the fourth week of the statin treatment. Furthermore an
      increase in the antioxidant enzymes following fluvastatin may be a clue for the
      antioxidant effects of this drug. Four weeks of fluvastatin long-acting tablets
      80 mg/day led to a decrease in plasma Apo-MDA and MDA levels. CONCLUSION: The
      findings of the present study demonstrate that fluvastatin 80 mg long-acting
      tablets may be used safely for 4 weeks and decrease atherogenic lipoproteins in
      KTPs. Furthermore, after 4 weeks of fluvastatin treatment, the levels of
      antioxidant parameters increased and oxidative parameters decreased. Further
      placebo-controlled treatment studies would be helpful to evaluate the effects of 
      fluvastatin on oxidant and antioxidant parameters including PON1 in patients with
      KT.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Yildiz, A
AU  - Yildiz A
AD  - Department of Nephrology, Uludag University Medical School, Bursa, Turkey.
      Electronic address: mecityildiz@gmail.com.
FAU - Gul, C B
AU  - Gul CB
AD  - Department of Nephrology, Bursa Sevket Yilmaz Training and Research Hospital,
      Bursa, Turkey.
FAU - Ocak, N
AU  - Ocak N
AD  - Department of Biochemistry, Uludag University Medical School, Bursa, Turkey.
FAU - Ersoy, A
AU  - Ersoy A
AD  - Department of Nephrology, Uludag University Medical School, Bursa, Turkey.
FAU - Sag, S
AU  - Sag S
AD  - Department of Cardiology, Uludag University Medical School, Bursa, Turkey.
FAU - Oruc, A
AU  - Oruc A
AD  - Department of Nephrology, Uludag University Medical School, Bursa, Turkey.
FAU - Ayar, Y
AU  - Ayar Y
AD  - Department of Nephrology, Uludag University Medical School, Bursa, Turkey.
FAU - Dagel, T
AU  - Dagel T
AD  - Department of Nephrology, Bursa Sevket Yilmaz Training and Research Hospital,
      Bursa, Turkey.
FAU - Dirican, M
AU  - Dirican M
AD  - Department of Biochemistry, Uludag University Medical School, Bursa, Turkey.
FAU - Gullulu, M
AU  - Gullulu M
AD  - Department of Nephrology, Uludag University Medical School, Bursa, Turkey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Apolipoproteins B)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Indoles)
RN  - 4L066368AS (fluvastatin)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.11.1.9 (Glutathione Peroxidase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EC 3.1.1.- (Carboxylic Ester Hydrolases)
RN  - EC 3.1.1.2 (arylesterase)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
SB  - IM
MH  - Adult
MH  - Apolipoproteins B/blood
MH  - Aryldialkylphosphatase/blood
MH  - Carboxylic Ester Hydrolases/blood
MH  - Erythrocytes/metabolism
MH  - Fatty Acids, Monounsaturated/*therapeutic use
MH  - Female
MH  - Glutathione Peroxidase/blood
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Indoles/*therapeutic use
MH  - *Kidney Transplantation
MH  - Lipid Peroxidation/drug effects
MH  - Male
MH  - Malondialdehyde/blood
MH  - Oxidative Stress/*drug effects
MH  - Superoxide Dismutase/blood
MH  - *Transplant Recipients
EDAT- 2015/12/29 06:00
MHDA- 2016/08/04 06:00
CRDT- 2015/12/29 06:00
PHST- 2015/08/08 00:00 [received]
PHST- 2015/09/27 00:00 [revised]
PHST- 2015/10/07 00:00 [accepted]
PHST- 2015/12/29 06:00 [entrez]
PHST- 2015/12/29 06:00 [pubmed]
PHST- 2016/08/04 06:00 [medline]
AID - S0041-1345(15)01019-2 [pii]
AID - 10.1016/j.transproceed.2015.10.027 [doi]
PST - ppublish
SO  - Transplant Proc. 2015 Dec;47(10):2870-4. doi: 10.1016/j.transproceed.2015.10.027.